9/24/2009
MedImmune Receives Highest Honor from The Gazette of Politics and Business
Gaithersburg, Md. – MedImmune was named by The Gazette of Politics and Business as the top business in the State of Maryland. The list of the 53 top businesses and organizations in the state was released at an awards ceremony held September 23, 2009. It acknowledges the top 53 businesses and organizations in Maryland based on annual revenue, employee growth, product or service innovations, community service efforts, steerage through the economic downturn, and reasons they are good places to work.
“I applaud these exceptional Maryland businesses that are consistently on the leading edge of innovation and doing their part to help through their pro-active community service programs. To make the 53 list is a great accomplishment,” said Cliff Chiet, publisher of The Gazette P&B. MedImmune will be profiled in a special section as part of the September 25, 2009 edition of The Gazette of Politics and Business.
MedImmune was recognized for its exceptional growth, community service programs in health and science, education for young people, and innovative scientific and medical technology. Toni Stiefel, director, corporate responsibility and community affairs, accepted the award for MedImmune and noted, “We are extremely honored to be recognized by the Gazette for doing exactly what we are passionate about—helping patients and our community live better lives. The work our employees do outside of our laboratories and manufacturing sites is as important as the technological advancements that we make inside our facilities.”
About MedImmune
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at
